Pre-Bid now on 2000+ items! Our live auction is happening next Wednesday, November 2nd!

Current Location:
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Send us your Comments

Never Miss a Story

Sign Up For Weekly Top Stories


More Industry Headlines

FDA docket workshop day one: no easy answers A range of valid viewpoints were brought to the podium in Silver Springs, Maryland today

Low intensity ultrasound doesn’t improve recovery after surgery: international clinical trial Will this be the end of this popular treatment?

Baystate Health hit by 'phishing' attack Information on 13,000 patients was exposed to the cyber-invaders

Philips submits study to FDA to expand indications for its digital pathology solution Only one percent difference between digital and optical diagnosis

Can MR detect Alzheimer's before symptoms have even appeared? MGH team combines analytics and imaging to make brain asymmetry a dementia biomarker

FDA to radiologists: stop using any Multidata Systems devices At least two devices distributed in U.S. without FDA approval

NJ law mandating dense breasts ultrasound and MR finds more cancer, reduces biopsies Requires insurance companies to pay for supplemental screening

FDA announces effort to 'modernize' device malfunction and injury reporting Curbing 'limited' reporting of adverse incidents

How affordable toxicology, testing fight the drug epidemic More than 28,000 people died from opioid overdose in 2014

Precision medicine is having a big impact on breast cancer chemo decisions: study Test distinguishes high risk of recurrence from low risk

Blood test may beat
imaging in cancer prediction

Blood test could detect lung cancer up to five years before CT scans

by Brendon Nafziger , DOTmed News Associate Editor
A blood test could detect about half of lung cancers up to five years before other tests, according to a team of British scientists.

In a series of papers to be presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago, the scientists from the company Oncimmune tout their "Early CDT-Lung Test" for finding around 40 percent of lung cancers years before they show up on CT scans.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material, camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

The company hopes the test, commercially available in the United States starting Tuesday, will not only save lives by detecting cancer early, but drive down health care costs.

The test works by looking for antibodies, called auto-antibodies, which the body produces to combat cancer.

As Geoffrey Hamilton-Fairley, executive chairman of Oncimmune, explained to DOTmed News, cancer cells divide rapidly. During division, they release antigens that the body recognizes as foreign, which it combats with auto-antibodies.

"Everybody has a background count of these auto-antibodies," Hamilton-Fairley said, which actually increase as we age, possibly because our bodies are fighting off many less aggressive cancers successfully.

The research originated with John Robertson, a professor at the University of Nottingham. As part of their yearly check-up, his patients at high-risk for breast cancer had their blood drawn. If they came down with cancer, Robertson went back to their blood samples and retroactively tested them for the auto-antibodies, finding that over half of the cancers could have been found four years before diagnosis.

For the current test, patients have their blood samples mailed to Oncimmune's U.S. testing facility in De Soto, Kan., just outside Kansas City.

The researchers then choose a selection of around six antigens that they pass a patient's blood sample over. If auto-antibodies are present, they'll bind to the antigens. After doing this a few times for accuracy, researchers develop the patient's antigen "fingerprint." This fingerprint is then compared against a population cut-off to judge the patient's risk for developing cancer.

Eventually, physicians will compare a patient's fingerprint against those taken from previous years, and not just population cut-offs, for more accurate readings, Hamilton-Fairley said.

"We'll end up with your own individual antigen fingerprint," he said, "and you'll be able to compare that year by year, and over time you'll pay more attention if you stray from the personal profile."

For now, they recommend one test about every five years, but as the patient ages or if there are risk factors - specifically, smoking - doctors might look at it more often.
  Pages: 1 - 2 - 3 >>


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2016 DOTmed.com, Inc.